NORTH CHICAGO, IL
Skyrizi cleared for pediatric psoriatic disease
- Sponsor
- AbbVie $ABBV
- Drug
- Skyrizi · risankizumab-rzaa
- Indication
- Moderate-to-severe plaque psoriasis and active psoriatic arthritis in patients aged 6 and older
FDA approved Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, expanding its existing adult indications into the pediatric age group.
Read original at drugs.com ↗Drug Watch — recent news on Skyrizi
- Integrated Long-Term Safety of Risankizumab in Psoriasis and Psoriatic Arthritis - HCP Live
- Your Good Health: Doctor recommends aggressive treatment for Crohn’s disease - Times Colonist
- Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape? - HCP Live
- How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD - HCP Live
- J&J’s Tremfya remains on top in Q2 pharma ad spending league as overall outlay drops - Fierce Pharma
Sponsor Watch — recent news on AbbVie
- SpaceX Lands With a Thud
- J&J's Innovative Medicine Unit Proves Its Resilience in Q2
- AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower
- Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)